Photo by lukeporter from unsplash
Letter to the Editor, With interest, we read the article by Jain et al.[1] about two patients, a 22‐year‐old male (patient‐1) and a 74‐year‐old female (patient‐2) both of whom developed… Click to show full abstract
Letter to the Editor, With interest, we read the article by Jain et al.[1] about two patients, a 22‐year‐old male (patient‐1) and a 74‐year‐old female (patient‐2) both of whom developed Guillain–Barre syndrome (GBS) 14 days and 3 days, respectively, after receiving the first AstraZeneca vaccine dose. Both patients were diagnosed with acute, motor and sensory, axonal neuropathy (AMSAN); however, in patient‐2, dysautonomia was additionally suspected.[1] The study is promising but raises concerns.
Keywords:
consider alternative;
guillain barre;
dysautonomia;
alternative causes;
barre syndrome
Journal Title: Annals of Indian Academy of Neurology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of Indian Academy of Neurology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!